PT  - JOURNAL ARTICLE
AU  - M Grochowicki
AU  - Y Khalfallah
AU  - A Vighetto
AU  - S Berquet
AU  - G Sassolas
TI  - Ophthalmic results in patients with macroprolactinomas treated with a new prolactin inhibitor CV 205-502.
AID  - 10.1136/bjo.77.12.785
DP  - 1993 Dec 01
TA  - British Journal of Ophthalmology
PG  - 785--788
VI  - 77
IP  - 12
4099  - http://bjo.bmj.com/content/77/12/785.short
4100  - http://bjo.bmj.com/content/77/12/785.full
SO  - Br J Ophthalmol1993 Dec 01; 77
AB  - Macroprolactinomas are pituitary tumours which have been effectively treated medically since the introduction of bromocriptine. The visual function of 13 patients treated with a new prolactin (PRL) inhibitor CV 205-502 (Sandoz Basle), a potent and selective dopamine D2 receptor agonist, was evaluated. This is the first detailed ophthalmic report of the use of this drug in macroprolactinomas. Patients were enrolled from June 1988 to July 1990 (mean follow up 30 months). Visual function including visual acuity, ocular pressure, and visual fields was regularly controlled. Visual fields (VF) were tested with Goldmann and automatic static perimetry (Vision Monitor). Treatment was globally effective. No modifications of the visual function were observed in nine patients (six normal, three previous VF losses after surgery). In four other patients, visual function dramatically improved (regression of a III paresis, one case; disappearance of a chiasmatic syndrome, three cases). A pituitary necrosis was observed in one case and successfully cured. CV 205-502 seems to be an effective and well tolerated treatment of macroprolactinomas.